ConductScience.org, home

Paper35907261

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.

Yabut JM and 1 other. Endocr Rev, 2023. Cited by 151 papers, by iCite.

Cite this record

ConductScience Library. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Papers, record 35907261. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35907261

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.
PubMed
Journal
Endocr Rev
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
151
iCite
Relative citation ratio, by iCite
15.9
iCite
Revised in PubMed
2025-01-03
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yabut JMJulian M
2Drucker DJDaniel Jhttps://orcid.org/0000-0001-6688-8127

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Non-alcoholic Fatty Liver DiseaseMajor topic
Diabetes Mellitus, Type 2Major topic
Humans
Glucagon-Like Peptide 1
Obesity
Inflammation
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor Agonists

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
154321CIHRCanadaPubMed

Source PubMed

Download CSV of grants

Cited by104

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 151 citations.

PMIDTitleJournalYearIn PapersSource
42713454Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant.Gastroenterol Hepatol (N Y)2026https://conductscience.org/library/papers/42713454PubMed
42697915Comment on: GLP-1 receptor agonists and male sexual health: translating cardiometabolic benefits into erectile outcomes.Int J Impot Res2026https://conductscience.org/library/papers/42697915PubMed
42588152The MASLD-Cardio-Oncology Triangle: Dietary Patterns, Metabolic Remodelling and Implications for Cancer Therapy Tolerance.Nutrients2026https://conductscience.org/library/papers/42588152PubMed
42538520The Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review.Mol Neurobiol2026https://conductscience.org/library/papers/42538520PubMed
42416572Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives.Rev Cardiovasc Med2026https://conductscience.org/library/papers/42416572PubMed
42367867Novel bile salt analogs reduce lipid accumulation in liver cells with potential to treat both metabolic dysfunction-associated steatotic liver disease and Clostridioides difficile infection.bioRxiv2026https://conductscience.org/library/papers/42367867PubMed
42366210Biologics for cardiovascular diseases: from bench to bedside.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42366210PubMed
42352264Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease.Biomolecules2026https://conductscience.org/library/papers/42352264PubMed
42318205Effects of SGLT-2 inhibitors and GLP-1 receptor agonists on liver function in patients with non-alcoholic fatty liver disease and type 2 diabetes.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42318205PubMed
42307179The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies.Biosci Rep2026https://conductscience.org/library/papers/42307179PubMed
42292219Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.Front Med (Lausanne)2026https://conductscience.org/library/papers/42292219PubMed
42271434GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42271434PubMed
42241516Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.Circ Res2026https://conductscience.org/library/papers/42241516PubMed
42222506Exendin-4 protects brain endothelial cell damage against hyperammonemic condition.Biochem Biophys Rep2026https://conductscience.org/library/papers/42222506PubMed
42206026Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages.Front Immunol2026https://conductscience.org/library/papers/42206026PubMed
42205663Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury.Cureus2026https://conductscience.org/library/papers/42205663PubMed
42201157Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.Vision (Basel)2026https://conductscience.org/library/papers/42201157PubMed
42171681GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and translational implications: a review.J Endocrinol Invest2026https://conductscience.org/library/papers/42171681PubMed
42117589Glucagon-Like Peptide-1 Receptor Agonist Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes in the All of Us Research Program.Am J Gastroenterol2026https://conductscience.org/library/papers/42117589PubMed
42072734Emerging Insights into the Liver-Pancreas Axis: A Central Hub in the Pathogenesis of Diabetes and Metabolic Diseases.Biomolecules2026https://conductscience.org/library/papers/42072734PubMed

See all 104 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35907261

GET https://conductscience.org/api/papers/v1/35907261/cited_by?page=2